For how we live.
An 840-child US trial gave the antibiotic to toddlers with moderate-to-severe wheezing in the emergency department. Symptom scores were no better than placebo, and the study was stopped for futility.
The AVENIR trial met its resistance endpoint in the gut but not the nose: giving the antibiotic to under-fives lifted macrolide resistance 16% above placebo communities.
Zoliflodacin is the first antibiotic developed solely for gonorrhoea in decades, and a non-profit holds the rights to register it across most of the world.
New EGASP surveillance data released for World AMR Awareness Week show cefixime resistance up from 1.7% to 11% and ciprofloxacin resistance at 95% across 12 reporting countries.